110 related articles for article (PubMed ID: 12114214)
1. Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activities.
Penington DJ; Bryant I; Riese DJ
Cell Growth Differ; 2002 Jun; 13(6):247-56. PubMed ID: 12114214
[TBL] [Abstract][Full Text] [Related]
2. Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners.
Li Z; Mei Y; Liu X; Zhou M
Cell Signal; 2007 Mar; 19(3):466-71. PubMed ID: 16978839
[TBL] [Abstract][Full Text] [Related]
3. ErbB kinases and NDF signaling in human prostate cancer cells.
Grasso AW; Wen D; Miller CM; Rhim JS; Pretlow TG; Kung HJ
Oncogene; 1997 Nov; 15(22):2705-16. PubMed ID: 9400997
[TBL] [Abstract][Full Text] [Related]
4. Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase.
Hobbs SS; Cameron EM; Hammer RP; Le AT; Gallo RM; Blommel EN; Coffing SL; Chang H; Riese DJ
Oncogene; 2004 Jan; 23(4):883-93. PubMed ID: 14661053
[TBL] [Abstract][Full Text] [Related]
5. Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development.
Kiguchi K; Bol D; Carbajal S; Beltrán L; Moats S; Chan K; Jorcano J; DiGiovanni J
Oncogene; 2000 Aug; 19(37):4243-54. PubMed ID: 10980598
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors.
Alimandi M; Wang LM; Bottaro D; Lee CC; Kuo A; Frankel M; Fedi P; Tang C; Lippman M; Pierce JH
EMBO J; 1997 Sep; 16(18):5608-17. PubMed ID: 9312020
[TBL] [Abstract][Full Text] [Related]
7. ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation.
Feroz K; Williams E; Riese DJ
Cell Signal; 2002 Sep; 14(9):793-8. PubMed ID: 12034361
[TBL] [Abstract][Full Text] [Related]
8. Phe45 of NRG2beta is critical for the affinity of NRG2beta for ErbB4 and for potent stimulation of ErbB4 signaling by NRG2beta*.
Hobbs SS; Gallo RM; Riese DJ
Growth Factors; 2005 Dec; 23(4):273-83. PubMed ID: 16338790
[TBL] [Abstract][Full Text] [Related]
9. Constitutive activation of the neuregulin-1/ErbB receptor signaling pathway is essential for the proliferation of a neoplastic Schwann cell line.
Frohnert PW; Stonecypher MS; Carroll SL
Glia; 2003 Aug; 43(2):104-18. PubMed ID: 12838503
[TBL] [Abstract][Full Text] [Related]
10. The neuregulin-I/ErbB signaling system in development and disease.
Britsch S
Adv Anat Embryol Cell Biol; 2007; 190():1-65. PubMed ID: 17432114
[TBL] [Abstract][Full Text] [Related]
11. Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation.
Contessa JN; Abell A; Mikkelsen RB; Valerie K; Schmidt-Ullrich RK
Breast Cancer Res Treat; 2006 Jan; 95(1):17-27. PubMed ID: 16267617
[TBL] [Abstract][Full Text] [Related]
12. Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4.
Jackson-Fisher AJ; Bellinger G; Shum E; Duong JK; Perkins AS; Gassmann M; Muller W; Kent Lloyd KC; Stern DF
Oncogene; 2006 Sep; 25(41):5664-72. PubMed ID: 16652155
[TBL] [Abstract][Full Text] [Related]
13. Widespread expression of ErbB2, ErbB3 and ErbB4 in non-human primate brain.
Thompson M; Lauderdale S; Webster MJ; Chong VZ; McClintock B; Saunders R; Weickert CS
Brain Res; 2007 Mar; 1139():95-109. PubMed ID: 17280647
[TBL] [Abstract][Full Text] [Related]
14. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.
Alimandi M; Romano A; Curia MC; Muraro R; Fedi P; Aaronson SA; Di Fiore PP; Kraus MH
Oncogene; 1995 May; 10(9):1813-21. PubMed ID: 7538656
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas.
Andersson U; Guo D; Malmer B; Bergenheim AT; Brännström T; Hedman H; Henriksson R
Acta Neuropathol; 2004 Aug; 108(2):135-42. PubMed ID: 15148612
[TBL] [Abstract][Full Text] [Related]
16. Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells.
Jannot CB; Beerli RR; Mason S; Gullick WJ; Hynes NE
Oncogene; 1996 Jul; 13(2):275-82. PubMed ID: 8710366
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
18. Activation of erbB2 and c-src in phorbol ester-treated mouse epidermis: possible role in mouse skin tumor promotion.
Xian W; Rosenberg MP; DiGiovanni J
Oncogene; 1997 Mar; 14(12):1435-44. PubMed ID: 9136987
[TBL] [Abstract][Full Text] [Related]
19. Requirement for ErbB2/ErbB signaling in developing cartilage and bone.
Fisher MC; Clinton GM; Maihle NJ; Dealy CN
Dev Growth Differ; 2007 Aug; 49(6):503-13. PubMed ID: 17555517
[TBL] [Abstract][Full Text] [Related]
20. c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function.
Ishizawar RC; Miyake T; Parsons SJ
Oncogene; 2007 May; 26(24):3503-10. PubMed ID: 17173075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]